Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01288521 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients
A Phase 4 study, sponsored by Sony Tuteja.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT01288521: Completed Phase 4 study, sponsored by Sony Tuteja.
NCT01288521 is a Phase 4 study that has completed, run by Sony Tuteja. The registered enrollment target is 8 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01288521, a Phase 4 study, has completed, sponsored by Sony Tuteja.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
Solid organ transplant recipients would greatly benefit from pharmacogenetic evaluation since immunosuppressive drug regimens consist of multiple medications with narrow therapeutic ranges and toxic adverse event profiles. Tacrolimus is a potent immunosuppressive agent utilized for rejection prophylaxis. Intensive pharmacokinetic monitoring must be performed following organ transplantation to ensure therapeutic drug concentrations due to its highly variable pharmacokinetics profile and narrow therapeutic index. Tacrolimus is a substrate for CYP450 3A and for the membrane transporter p-glycoprotein (Pgp). Polymorphisms in the gene encoding for CYP3A5 have been extensively studied and have been found to influence the dosing of tacrolimus. The effect of ABCB1 gene polymorphisms (which encodes for Pgp) upon tacrolimus pharmacokinetics has been more difficult to establish. This study will determine if haplotypes derived from three frequent polymorphisms in the ABCB1 gene (C1236T, G2677T, C3435T) can predict the degree of drug interaction between tacrolimus (CYP3A5/Pgp substrate) and ketoconazole (CYP3A5/Pgp inhibitor) in patients who are CYP3A5 nonexpressors. This prospective pharmacokinetic and pharmacogenomic study will enroll 20 stable renal transplant recipients with the CYP3A5 \*3/\*3 genotype and grouped by ABCB1 haplotype (CGC vs TTT). Pharmacokinetics of tacrolimus will be assessed on 2 occasions with and without ketoconazole coadministration separated by 1 week. The order of study occasions will be randomized in a crossover design. The results of this study may identify a genomic marker for predicting drug-drug interactions. Knowing this information a priori will aid clinicians in modifying drug dosing and alleviate patients of the burden of significant drug toxicities.
Primary Outcome
Tac bioavailability alone vs. Tac bioavailability with Keto. To determine F we took the ratio of area under the curve of the oral dose divided by the area under the curve of the IV dose. F was determined by fitting a model that considered the plasma concentration of tac with IV vs. oral dosing.
Interventions
- DRUG Tacrolimus + Ketoconazole, Then Tacrolimus alone
- DRUG Tacrolimus alone, Then Tacrolimus + Ketoconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-09 |
| Phase | Phase 4 |
What the finished NCT01288521 record still lists
NCT01288521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Tacrolimus + Ketoconazole, Then Tacrolimus alone is the first listed.
NCT01288521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01288521 about?
NCT01288521 is a clinical study titled "Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients". Solid organ transplant recipients would greatly benefit from pharmacogenetic evaluation since immunosuppressive drug regimens consist of multiple medications with narrow therapeutic ranges and toxic adverse event profiles. Tacrolimus is a potent immunosuppressive agent utilized for rejection prophyl...
What is the current status of trial NCT01288521?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2008-10. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01288521?
The interventions under investigation include: Tacrolimus + Ketoconazole, Then Tacrolimus alone (DRUG), Tacrolimus alone, Then Tacrolimus + Ketoconazole (DRUG).
Who is sponsoring clinical trial NCT01288521?
This trial is sponsored by Sony Tuteja, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01288521's enrollment target sits among peer trials
8 1972nd of 2000 higher than 20 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia